Preclinical studies in retinoblastoma models have also shown encouraging results: the HDAC6 inhibitor WT161 induces apoptosis and sensitizes tumor cells to cisplatin [35], whereas intravitreal belinostat effectively eradicates vitreous seeds with minimal retinal toxicity. Here, HDAC6 is linked to neoplasm.